Key Points
- Insider Shane William Charles Kovacs sold 100,000 shares of OLMA on Jan. 15 at an average price of $28.73 for about $2.87M, cutting his stake by 41.7% to 139,727 shares (he also sold 3,822 shares on Jan. 13).
- Multiple brokers have recently upgraded OLMA and lifted price targets—consensus target ≈ $41 with Citigroup at $60—resulting in a MarketBeat consensus rating of "Moderate Buy."
- Olema is a clinical‑stage biotech whose lead candidate, OP‑1250, is in Phase 3 for ER+ breast cancer; the company has a roughly $2.0B market cap, negative earnings, and a 12‑month trading range of $2.86–$36.26, indicating high volatility.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) insider Shane William Charles Kovacs sold 3,822 shares of the business's stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $28.01, for a total transaction of $107,054.22. Following the completion of the sale, the insider directly owned 239,727 shares of the company's stock, valued at approximately $6,714,753.27. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shane William Charles Kovacs also recently made the following trade(s):
- On Thursday, January 15th, Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $28.73, for a total transaction of $2,873,000.00.
Olema Pharmaceuticals Trading Up 1.5%
Olema Pharmaceuticals stock opened at $29.19 on Friday. Olema Pharmaceuticals, Inc. has a one year low of $2.86 and a one year high of $36.26. The stock has a 50-day moving average of $24.70 and a two-hundred day moving average of $13.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. The stock has a market cap of $2.00 billion, a PE ratio of -15.61 and a beta of 1.92.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). On average, research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have recently commented on OLMA shares. The Goldman Sachs Group lifted their price target on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a "buy" rating in a report on Thursday, December 11th. JPMorgan Chase & Co. raised their price objective on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 18th. Citigroup boosted their target price on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a "buy" rating in a report on Friday, December 12th. Piper Sandler initiated coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They set an "overweight" rating and a $40.00 price target on the stock. Finally, Guggenheim started coverage on Olema Pharmaceuticals in a report on Wednesday, October 8th. They issued a "buy" rating and a $20.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $41.00.
Check Out Our Latest Analysis on Olema Pharmaceuticals
Hedge Funds Weigh In On Olema Pharmaceuticals
Several hedge funds have recently made changes to their positions in OLMA. Paradigm Biocapital Advisors LP boosted its holdings in shares of Olema Pharmaceuticals by 0.4% in the third quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company's stock valued at $66,515,000 after acquiring an additional 30,000 shares during the period. Deep Track Capital LP raised its stake in shares of Olema Pharmaceuticals by 0.8% during the 3rd quarter. Deep Track Capital LP now owns 3,470,172 shares of the company's stock worth $33,973,000 after buying an additional 27,339 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Olema Pharmaceuticals by 22.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company's stock worth $5,650,000 after purchasing an additional 242,997 shares during the period. Candriam S.C.A. increased its holdings in shares of Olema Pharmaceuticals by 46.9% in the 3rd quarter. Candriam S.C.A. now owns 1,249,727 shares of the company's stock valued at $12,235,000 after purchasing an additional 399,273 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of Olema Pharmaceuticals by 193.4% in the second quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company's stock valued at $4,996,000 after purchasing an additional 773,064 shares during the period. Hedge funds and other institutional investors own 91.78% of the company's stock.
Key Stories Impacting Olema Pharmaceuticals
Here are the key news stories impacting Olema Pharmaceuticals this week:
- Positive Sentiment: Broker upgrades and higher price targets from multiple firms (Citigroup, Oppenheimer, Piper Sandler, Goldman Sachs) lifted analyst support and raised consensus upside (average target ≈ $41), which likely boosted investor confidence. MarketBeat Analyst Coverage
- Positive Sentiment: Olema published an investor presentation emphasizing its palazestrant (OP‑1250) development strategy and combination plans with CDK4/6 inhibitors — useful context for upcoming data and commercial potential that can support the stock. Investor Presentation
- Neutral Sentiment: Institutional ownership is very high (~91.8%), and a mix of recent modest institutional buys/sells was reported — this large institutional base can amplify moves but is not an immediate directional catalyst. Institutional Holdings
- Negative Sentiment: Significant insider selling was disclosed this week: Shane Kovacs sold 100,000 shares (~$2.87M at $28.73) and additional smaller lots; Director/insider David Myles sold multiple blocks (including 50,000 at ~$27.60 and 10,000 at ~$28.34). Large insider sales (noted ownership percentage drops) can weigh on sentiment even if management retains meaningful stakes. Kovacs SEC Filing Myles SEC Filing
Olema Pharmaceuticals Company Profile
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
